PHAnews is meant to give a picture
of recent events
and activities affecting the life of the PH community.
This compilation should not be viewed as endorsement
of the information provided or its accuracy.
From
the PHA President...
"In 1985, the only database
for pulmonary hypertension funded by the federal
government closed after five years. A total of
187 patients had been identified throughout the
entire U.S. There were no disease-specific treatments.
Patients had a 50% chance of living 2.8 years.
Today - only 20 years later
- ...there are five approved treatments and more
on the way…treating tens of thousands of patients.
Doctors are learning to pay attention and diagnose
this illness. Today, pulmonary hypertension is
becoming manageable. Today, patients are living
longer....Pulmonary hypertension is a marginalized
and unknown illness no more. Tomorrow, we look
towards the cure."
Myogen Reports Positive Top Line Results for Ambrisentan Phase 3 Trial in Pulmonary Arterial Hypertension
Dec. 12 -- Myogen, Inc. (Nasdaq:
MYOG - News) today announced positive top line results
of the ARIES-2 trial, the first pivotal Phase 3 trial
evaluating ambrisentan, an oral endothelin receptor
antagonist (ERA), in pulmonary arterial hypertension
(PAH). The trial met the primary efficacy endpoint
of improved exercise capacity, the key secondary endpoint
of time to clinical worsening and several other secondary
efficacy endpoints.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information
resource for people dealing with PH -- they have ARRIVED
and are ready to ship!!!
The author, a PH patient
herself, knows what it is like to live with the disease.
She talked to many other patients, doctors, and researchers
while writing the Survival Guide. Dr. Ronald J. Oudiz
and a team of physicians with a deep knowledge of
PH edited the book for accuracy.
New edition contains
a chart of 15 drugs used to treat
PH; results of recent clinical trials;
in-depth discussion of PH secondary to other
diseases or conditions; a new chapter on
what to eat if you have PH; and much,
much more!
United Therapeutics Announces Positive Results from Trust Study of Intravenous Remodulin(R)
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 19 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the preliminary results of its 45-patient placebo-controlled TRUST trial are positive, (p=0.00767). Specifically, intravenous Remodulin produced an 83-meter median improvement in six-minute walk distance compared to placebo after twelve weeks in patients with NYHA Class III/IV pulmonary arterial hypertension. Supporting and secondary endpoint analyses of the study results are ongoing.
PR Pharmaceuticals Files IND for Pulmonary Hypertension
FORT COLLINS, Colo., Dec. 20 /PRNewswire/ -- PR Pharmaceuticals, Inc.
(PRP), announced today that it filed an Investigational New Drug (IND)
application with the U.S. Food and Drug Administration (FDA) for the Company's
first clinical product, PulmoLAR(TM) (2-methoxyestradiol) for the treatment of
pulmonary arterial hypertension (PAH).
PHA has created an
online slideshow to answer your questions about Medicare
Part D, Medicare’s new prescription drug option.
This presentation is intended for both medical professionals
AND patients.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
